Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.
Checked against the public recordLast updated Feb 5, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Merck Sharp & Dohme LLC
- Interventions being studied
- Biological: 9vHPV Vaccine; Biological: mRNA-1273 Vaccine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Has not yet had coitarche and does not plan on becoming sexually active during the vaccination period * Participant or participant's legally acceptable representative can read, understand, and complete the electronic vaccination report card (eVRC). Exclusion Criteria: * Known allergy to any vaccine component * History of severe allergic reaction that required medical intervention * Thrombocytopenia or any coagulation disorder * Has a history of myocarditis or pericarditis * Has a history of a clinical or microbiological diagnosis of COVID-19 ≤90 days prior to Day 1 visit or history of multisystem inflammatory syndrome in children (MIS-C) at any time prior to Day 1 visit * Females only: participant is pregnant * Currently immunocompromised, or been diagnosed with immunodeficiency * Had a splenectomy * Receiving or has received immunosuppressive therapies within the last year * Received any immunoglobulin product or blood-derived product within 3 months * Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cognitive Clinical Trials, LLC ( Site 0054)Phoenix, Arizona
- Eclipse Clinical Research ( Site 0095)Tucson, Arizona
- Children's Clinic of Jonesboro, PA ( Site 0044)Jonesboro, Arkansas
- Preferred Research Partners Inc. ( Site 0092)Little Rock, Arkansas
- Coast Clinical Research, LLC ( Site 0027)Bellflower, California
- Ark Clinical Research ( Site 0098)Long Beach, California
- Valley Clinical Trials Inc. ( Site 0004)Northridge, California
- Medical Center for Clinical Research ( Site 0051)San Diego, California
- Ark Clinical Research ( Site 0108)Tustin, California
- Emerson Clinical Research Institute ( Site 0021)Washington D.C., District of Columbia
- Accel Research Sites-DeLand Clinical Research Unit ( Site 0066)DeLand, Florida
- Advanced Research for Health Improvement, LLC ( Site 0012)Immokalee, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 5, 2026. Always confirm current availability with the study team.